Benzinga
Benzinga
Noticias de España
Acciones
Índices
Bonos
ETFs
Economía
General
Noticias de EE.UU.
Acciones
Índices
Ganancias
Economía
Mercados de predicción
Mercados privados
Otros mercados
Calificaciones de analistas
Trading
Comunicados de prensa
Noticias Mundiales
Europa
Asia
Latinoamérica
Criptomonedas
Noticias
Altcoins
Bitcoin
Blockchain
Dogecoin
Ethereum
Shiba Inu
NFT
Formación
Invertir en criptomonedas
Invertir en acciones
Forex
Benzinga
sábado, noviembre 21
Noticias de España
Acciones
Índices
Bonos
ETFs
Economía
General
Noticias de EE.UU.
Acciones
Índices
Ganancias
Economía
Mercados de predicción
Mercados privados
Otros mercados
Calificaciones de analistas
Trading
Comunicados de prensa
Noticias Mundiales
Europa
Asia
Latinoamérica
Criptomonedas
Noticias
Altcoins
Bitcoin
Blockchain
Dogecoin
Ethereum
Shiba Inu
NFT
Formación
Invertir en criptomonedas
Invertir en acciones
Forex
Allarity Therapeutics Inc
ALLR
NASDAQ
Lista de seguimiento
Get Report
Trade with Public
Get Report
Trade with Public
$0.7850
-0.08
-9.25%
al cierre: Nov 20, 4:00 PM EST
$0.8000
0.015
1.91%
After hour: 7:29 PM EST
Get Report
Panorámica general
Noticias
Gráficos
Previsión de beneficios
Eventos
Precios objetivo
Finanzas
Sentimiento
Comparar
Informe de acciones
Allarity Therapeutics Financials
Allarity Therapeutics (ALLR) financial statements — income, revenue, gross margin and key metrics.
Earnings & Guidance News
PRO
Allarity Therapeutics Sees Q4 GAAP EPS $0.01-$0.04
Allarity Therapeutics (NASDAQ:ALLR) is looking for Q4 GAAP EPS of $0.01-$0.04
Benzinga Newsdesk
PRO
Allarity Therapeutics Sees FY2026 GAAP EPS $(0.76)-$(0.73) vs $(0.80) Est
Allarity Therapeutics (NASDAQ:ALLR) is looking for FY2026 GAAP EPS of $(0.76)-$(0.73) vs $(0.80) analyst estimate..
Benzinga Newsdesk
PRO
Allarity Therapeutics Q3 EPS $(0.39) Misses $(0.21) Estimate, Sales $5.000K
Allarity Therapeutics (NASDAQ:ALLR) reported quarterly losses of $(0.39) per share which missed the analyst consensus estimate of $(0.21) by 85.71 percent. This is a 105.26 percent decrease over losses of $(0.19) per
Benzinga Newsdesk
PRO
Allarity Therapeutics Q2 EPS $(0.21) Beats $(0.25) Estimate
Allarity Therapeutics (NASDAQ:ALLR) reported quarterly losses of $(0.21) per share which beat the analyst consensus estimate of $(0.25) by 16 percent. This is a 40 percent decrease over losses of $(0.15) per share from
Benzinga Newsdesk
PRO
Allarity Therapeutics Q1 EPS $(0.17) Beats $(0.22) Estimate, Sales $25.000K
Allarity Therapeutics (NASDAQ:ALLR) reported quarterly losses of $(0.17) per share which beat the analyst consensus estimate of $(0.22) by 22.73 percent. This is a 32 percent increase over losses of $(0.25) per share
Benzinga Newsdesk
PRO
Allarity Therapeutics Q4 EPS $(0.21), Inline, Sales $320.000K
Allarity Therapeutics (NASDAQ:ALLR) reported quarterly losses of $(0.21) per share which met the analyst consensus estimate. This is a 87.79 percent increase over losses of $(1.72) per share from the same period last
Benzinga Newsdesk